GoAI
Get started
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc.

XBIO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.59

+$0.20 · +5.90%

Aug 21, 4:00 PM ET

XBIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

70

Undervalued

Momentum

30

Weakening

Sentiment

61

Bullish

Risk resilience

15

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
James F. Parslow
Listed since
Jun 30, 2016
Employees
2

Market position

Day range

Current $3.59

52-week range

Current $3.59

Open
$3.36
Previous close
$3.39
Volume
84.26K
2.97× average
Average volume
28.33K
Average daily volume
Market cap
8.22M USD
Beta
2.15
Market reference 1
50-day average
$2.9221
+22.86% above average
200-day average
$2.7315
+31.43% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-4.19M USD
P/E (TTM)
-3.02×
P/B (TTM)
1.36×
P/S (TTM)
2.52×
EV / EBITDA
1.56×
Earnings yield
-72.60%
Free cash flow yield
-61.93%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-81.01%
Net margin
-75.90%
Return on equity
-36.25%
Return on assets
-32.05%
Return on invested capital
-38.33%

Financial health

Debt / equity
0×
Current ratio
8.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends160%-79%-317%-555%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -495.12%Operating margin, FY2022: -393.57%Operating margin, FY2023: -177.79%Operating margin, FY2024: -168.16%Operating margin, FY2025: -95.23%Net margin, FY2021: -486.36%Net margin, FY2022: -383.87%Net margin, FY2023: -162.78%Net margin, FY2024: -158.39%Net margin, FY2025: -90.07%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -495.12%. Operating margin FY2022 -393.57%. Operating margin FY2023 -177.79%. Operating margin FY2024 -168.16%. Operating margin FY2025 -95.23%. Net margin FY2021 -486.36%. Net margin FY2022 -383.87%. Net margin FY2023 -162.78%. Net margin FY2024 -158.39%. Net margin FY2025 -90.07%.

Income trends

Revenue

2.98M USD+19.04%

Operating income

−2.83M USD+32.58%

Net income

−2.68M USD+32.31%
Income trends across reported periods3.95M USD68.12K USD−3.81M USD−7.69M USDRevenue, FY2021: 1.16M USDRevenue, FY2022: 1.71M USDRevenue, FY2023: 2.54M USDRevenue, FY2024: 2.5M USDRevenue, FY2025: 2.98M USDOperating income, FY2021: −5.75M USDOperating income, FY2022: −6.72M USDOperating income, FY2023: −4.52M USDOperating income, FY2024: −4.2M USDOperating income, FY2025: −2.83M USDNet income, FY2021: −5.65M USDNet income, FY2022: −6.55M USDNet income, FY2023: −4.13M USDNet income, FY2024: −3.96M USDNet income, FY2025: −2.68M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.16M USD. Revenue FY2022 1.71M USD. Revenue FY2023 2.54M USD. Revenue FY2024 2.5M USD. Revenue FY2025 2.98M USD. Operating income FY2021 −5.75M USD. Operating income FY2022 −6.72M USD. Operating income FY2023 −4.52M USD. Operating income FY2024 −4.2M USD. Operating income FY2025 −2.83M USD. Net income FY2021 −5.65M USD. Net income FY2022 −6.55M USD. Net income FY2023 −4.13M USD. Net income FY2024 −3.96M USD. Net income FY2025 −2.68M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.98M USD2.5M USD2.54M USD1.71M USD1.16M USD
Gross profit2.98M USD2.5M USD2.54M USD1.71M USD1.16M USD
Research and development3.07M USD3.29M USD3.49M USD4.77M USD3.16M USD
Selling, general, and administrative2.75M USD3.42M USD3.56M USD3.65M USD3.74M USD
Operating expenses5.81M USD6.7M USD7.06M USD8.42M USD6.91M USD
Interest income148K USD249.86K USD355.76K USD167.15K USD100.47K USD
Depreciation and amortization—153.34K USD—27.04K USD35.48K USD
Operating income−2.83M USD−4.2M USD−4.52M USD−6.72M USD−5.75M USD
Net income−2.68M USD−3.96M USD−4.13M USD−6.55M USD−5.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
6 beats, 1 miss, 2 met estimates
Average EPS surprise
+5.65%
9 comparable reports
Latest EPS result
-0.41

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.12-0.33-0.55-0.77Q4 '24MissQ1 '25MetQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 12, 2024: actual -0.28, estimate -0.14, surprise -100.00%, Miss. Q1 2025, reported Mar 18, 2025: actual -0.68, estimate -0.68, surprise 0.00%, Met estimate. Q2 2025, reported May 12, 2025: actual -0.59, estimate -0.72, surprise +18.06%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.45, estimate -0.64, surprise +29.69%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.33, estimate -0.49, surprise +32.65%, Beat. Q1 2026, reported Mar 12, 2026: actual -0.22, estimate -0.52, surprise +57.69%, Beat. Q2 2026, reported May 12, 2026: actual -0.2, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual -0.41, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.07M858.92K647.04K435.16KQ4 '24MissQ1 '25MetQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26No estimateQ3 '26No estimate
Q4 2024, reported Nov 12, 2024: actual 614.24K USD, estimate 750K USD, surprise -18.10%, Miss. Q1 2025, reported Mar 18, 2025: actual 650K USD, estimate 650K USD, surprise 0.00%, Met estimate. Q2 2025, reported May 12, 2025: actual 590K USD, estimate 670K USD, surprise -11.94%, Miss. Q3 2025, reported Aug 12, 2025: actual 589.9K USD, estimate 479K USD, surprise +23.15%, Beat. Q4 2025, reported Nov 12, 2025: actual 1.03M USD, estimate 630K USD, surprise +63.01%, Beat. Q1 2026, reported Mar 12, 2026: actual 766.3K USD, estimate 690K USD, surprise +11.06%, Beat. Q2 2026, reported May 12, 2026: actual 806.92K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 660.6K USD, estimate —, surprise —, Comparison unavailable.

XBIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding XBIO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
31.83K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research XBIO

research.disclaimer